Generation Bio Announces Third Quarter 2025 Financial Results

Core Viewpoint - Generation Bio Co. reported its third quarter financial results for 2025, highlighting a significant decrease in cash reserves and a reduction in net loss compared to the same quarter in the previous year [1][2]. Financial Performance - Cash Position: As of September 30, 2025, cash, cash equivalents, and marketable securities totaled $89.6 million, down from $185.2 million as of December 31, 2024 [7]. - R&D Expenses: Research and development expenses increased to $21.7 million for the quarter ended September 30, 2025, compared to $15.1 million for the same quarter in 2024 [7]. - G&A Expenses: General and administrative expenses rose to $12.2 million for the quarter ended September 30, 2025, up from $9.2 million in the same quarter of 2024 [7]. - Net Loss: The net loss for the quarter was $5.5 million, or $0.82 per share, an improvement from a net loss of $15.3 million, or $2.29 per share, for the same quarter in 2024 [7][11]. Strategic Developments - Strategic Alternatives: In August 2025, the company initiated a process to evaluate strategic alternatives aimed at maximizing shareholder value, with no assurance that this will lead to a transaction [3].